Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K7 | O14733 | 11/20 | 0.45 |
| ▸ | KDR | P35968 | 7/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.38 |
| ▸ | TNNI3K | Q59H18 | 3/20 | 0.38 |
| ▸ | BRAF | P15056 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5318705 | 1.00 | MAP2K7 (0.45) | MAP2K7KDRHDAC3HDAC1HDAC2 | |
| SCHEMBL14447636 | 0.89 | MAP2K7 (0.42) | MAP2K7KDRMAPK14TNNI3KBRAF | |
| SCHEMBL5319484 | 0.88 | MAP2K7 (0.44) | MAP2K7KDRMAPK14TNNI3KBRAF | |
| SCHEMBL5319477 | 0.88 | MAP2K7 (0.44) | MAP2K7KDRMAPK14TNNI3KBRAF | |
| SCHEMBL5321099 | 0.86 | MAP2K7 (0.47) | MAP2K7KDRTNNI3K | |
| SCHEMBL5321103 | 0.86 | MAP2K7 (0.47) | MAP2K7KDRTNNI3K | |
| SCHEMBL5444516 | 0.84 | MAP2K7 (0.48) | MAP2K7KDRMAPK14TNNI3KBRAF | |
| SCHEMBL5318656 | 0.83 | MAP2K7 (0.47) | MAP2K7KDRMAPK14TNNI3KBRAF | |
| SCHEMBL5319331 | 0.83 | MAP2K7 (0.47) | MAP2K7KDRMAPK14TNNI3KBRAF | |
| SCHEMBL14447620 | 0.82 | MAP2K7 (0.45) | MAP2K7KDRHDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007076473-A2 | SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | BRAF, ARAF, RAF1 | MAP2K7 141/4885KDR 555/4885HDAC3 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.